X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (749) 749
salmeterol xinafoate (642) 642
albuterol - analogs & derivatives (616) 616
male (446) 446
female (442) 442
asthma - drug therapy (438) 438
salmeterol (396) 396
albuterol - therapeutic use (345) 345
middle aged (342) 342
albuterol - administration & dosage (340) 340
adult (339) 339
administration, inhalation (338) 338
albuterol - adverse effects (317) 317
asthma (315) 315
respiratory system (276) 276
bronchodilator agents - therapeutic use (268) 268
double-blind method (264) 264
fluticasone (258) 258
index medicus (258) 258
bronchodilator agents - administration & dosage (254) 254
aged (249) 249
drug therapy, combination (234) 234
bronchodilator agents - adverse effects (215) 215
adolescent (197) 197
treatment outcome (192) 192
pulmonary disease, chronic obstructive - drug therapy (187) 187
adrenergic beta-agonists - therapeutic use (176) 176
adrenergic beta-agonists - adverse effects (175) 175
drug therapy (167) 167
androstadienes - administration & dosage (154) 154
adrenergic beta-agonists - administration & dosage (147) 147
child (140) 140
formoterol fumarate (140) 140
asthma - physiopathology (132) 132
formoterol (128) 128
fluticasone propionate (117) 117
forced expiratory volume - drug effects (113) 113
salbutamol (113) 113
androstadienes - therapeutic use (112) 112
medicine, general & internal (111) 111
chronic obstructive pulmonary disease (107) 107
pharmacology & pharmacy (104) 104
drug combinations (103) 103
androstadienes - adverse effects (102) 102
dose-response relationship, drug (98) 98
inhaled corticosteroids (95) 95
anti-asthmatic agents - administration & dosage (94) 94
corticosteroids (93) 93
allergy (92) 92
cross-over studies (92) 92
albuterol (91) 91
copd (90) 90
adrenal cortex hormones - administration & dosage (86) 86
obstructive pulmonary-disease (86) 86
lung diseases, obstructive (83) 83
anti-asthmatic agents - adverse effects (82) 82
randomized controlled trials as topic (82) 82
ethanolamines - administration & dosage (81) 81
drug administration schedule (79) 79
anti-asthmatic agents - therapeutic use (77) 77
budesonide (77) 77
ethanolamines - adverse effects (77) 77
safety (76) 76
tiotropium bromide (76) 76
ethanolamines - therapeutic use (74) 74
exacerbations (74) 74
immunology (74) 74
quality of life (73) 73
efficacy (72) 72
forced expiratory volume (69) 69
time factors (69) 69
tiotropium (69) 69
adrenal cortex hormones - therapeutic use (66) 66
respiratory function tests (66) 66
pulmonary disease, chronic obstructive - physiopathology (63) 63
nebulizers and vaporizers (62) 62
research (62) 62
therapy (62) 62
double-blind (60) 60
albuterol - pharmacology (59) 59
dosage and administration (59) 59
mortality (58) 58
aged, 80 and over (57) 57
cardiac & cardiovascular systems (57) 57
scopolamine derivatives - therapeutic use (56) 56
care and treatment (55) 55
asthma - mortality (53) 53
critical care medicine (52) 52
agonist (51) 51
children (50) 50
respiratory tract diseases (48) 48
pulmonary and respiratory medicine (46) 46
pulmonary/respiratory (46) 46
adrenal cortex hormones - adverse effects (45) 45
adrenergic beta-2 receptor agonists - administration & dosage (44) 44
severity of illness index (44) 44
agonists (43) 43
bronchodilators (43) 43
child, preschool (43) 43
inflammation (43) 43
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (762) 762
German (17) 17
French (9) 9
Japanese (4) 4
Danish (3) 3
Spanish (3) 3
Chinese (2) 2
Norwegian (2) 2
Polish (2) 2
Romanian (2) 2
Hebrew (1) 1
Hungarian (1) 1
Portuguese (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Chest, ISSN 0012-3692, 04/1999, Volume 115, Issue 4, pp. 957 - 965
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2011, Volume 364, Issue 12, pp. 1093 - 1103
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1465-1858, 2015, Volume 2015, Issue 11, p. CD007949
Background Long‐acting beta2‐agonists (LABA) in combination with inhaled corticosteroids (ICS) are increasingly prescribed for children with asthma. Objectives... 
Asthma (chronic): combination/additive drug treatment | Formoterol Fumarate | Salmeterol Xinafoate | Lungs & airways | Adrenal Cortex Hormones | Anti‐Asthmatic Agents | Ethanolamines | Disease Progression | Asthma | Randomized Controlled Trials as Topic | Combination and additive therapies | Steroids, inhaled | Beclomethasone | Beta‐agonists, long‐acting | Asthma (chronic) | Child health | Asthma, chronic ‐ pharmacotherapy | Albuterol | Adrenergic beta‐Agonists | Drug Therapy, Combination | Medicine General & Introductory Medical Sciences | Chronic Disease | Combination/additive drug treatment | Anti-Asthmatic Agents - adverse effects | Humans | Male | Ethanolamines - administration & dosage | Salmeterol Xinafoate - adverse effects | Adrenergic beta-Agonists - administration & dosage | Albuterol - administration & dosage | Female | Child | Adrenergic beta-Agonists - adverse effects | Beclomethasone - administration & dosage | Formoterol Fumarate - adverse effects | Albuterol - analogs & derivatives | Salmeterol Xinafoate - administration & dosage | Asthma - drug therapy | Adrenal Cortex Hormones - adverse effects | Adolescent | Beclomethasone - adverse effects | Anti-Asthmatic Agents - administration & dosage | Adrenal Cortex Hormones - administration & dosage | Formoterol Fumarate - administration & dosage
Journal Article
International Journal of COPD, ISSN 1176-9106, 2018, Volume 13, pp. 3923 - 3936
Journal Article
European Respiratory Journal, ISSN 0903-1936, 10/2017, Volume 50, Issue 4, pp. 1700451 - 1700451
.... The aim was to determine the effects of inhaled corticosteroids on airway microbial load in COPD patients and evaluate the influence of the underlying inflammatory profile on airway colonisation and microbiome... 
MORTALITY | OBSTRUCTIVE PULMONARY-DISEASE | FLUTICASONE PROPIONATE | BLOOD EOSINOPHILS | RESPIRATORY SYSTEM | EXACERBATIONS | INNATE | RISK | PNEUMONIA | PROTEINS | EXPRESSION | Sputum - microbiology | Glucocorticoids - administration & dosage | Bronchodilator Agents - administration & dosage | Pulmonary Disease, Chronic Obstructive - microbiology | Humans | Middle Aged | Male | Drug Monitoring - methods | Salmeterol Xinafoate - adverse effects | Bacterial Load - drug effects | Forced Expiratory Volume | Respiratory Tract Infections - microbiology | Long Term Adverse Effects - microbiology | Pulmonary Disease, Chronic Obstructive - blood | Bacterial Load - methods | Female | Eosinophils - pathology | Bronchodilator Agents - adverse effects | Fluticasone - adverse effects | Glucocorticoids - adverse effects | Pulmonary Disease, Chronic Obstructive - diagnosis | Administration, Inhalation | Treatment Outcome | Salmeterol Xinafoate - administration & dosage | Respiratory Tract Infections - diagnosis | Long Term Adverse Effects - diagnosis | Fluticasone - administration & dosage | Respiratory Function Tests | Viral Load - drug effects | Viral Load - methods | Pulmonary Disease, Chronic Obstructive - drug therapy | Respiratory therapy | Corticoids | Leukocytes (eosinophilic) | Propionic acid | Salmeterol | Microbiomes | Inflammation | Fluticasone | Inhalation | Respiratory tract | Sputum | Bacteria | Chronic obstructive pulmonary disease | Long-term effects
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 04/2007, Volume 146, Issue 8, pp. 545 - 555
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2010, Volume 363, Issue 18, pp. 1715 - 1726
Journal Article
Medicine (United States), ISSN 0025-7974, 2015, Volume 94, Issue 51, p. e2306
A combination of long-acting anticholinergic agents (LAACs) and long-acting beta(2)-adrenergic receptor agonist (LABA) is effective in improving lung function... 
MORTALITY | MEDICINE, GENERAL & INTERNAL | EFFICACY | INFLAMMATION | EXACERBATIONS | TIOTROPIUM | ANTICHOLINERGICS | FIXED-DOSE COMBINATION | CARDIOVASCULAR SAFETY | GLYCOPYRRONIUM | SALMETEROL | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Male | Salmeterol Xinafoate - adverse effects | Fluticasone-Salmeterol Drug Combination - adverse effects | Stroke - chemically induced | Tiotropium Bromide - administration & dosage | Adrenergic beta-Agonists - administration & dosage | Aged, 80 and over | Female | Bronchodilator Agents - adverse effects | Cholinergic Antagonists - adverse effects | Adrenergic beta-Agonists - adverse effects | Tiotropium Bromide - adverse effects | Formoterol Fumarate - adverse effects | Administration, Inhalation | Salmeterol Xinafoate - administration & dosage | Cholinergic Antagonists - administration & dosage | Fluticasone-Salmeterol Drug Combination - administration & dosage | Budesonide, Formoterol Fumarate Drug Combination - adverse effects | Taiwan - epidemiology | Aged | Cardiovascular Diseases - chemically induced | Delayed-Action Preparations | Budesonide, Formoterol Fumarate Drug Combination - administration & dosage | Drug Combinations | Cohort Studies | Formoterol Fumarate - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Care and treatment | Usage | Cohort analysis | Research | Risk factors | Bronchodilator agents | Morbidity
Journal Article
Journal Article